Effect of Berberis root active component (Berberine) in patients with Type2 Diabetes.

The effect of Berberis root active component (Berberine) on blood sugar control in patients with Type2 Diabetes.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013040712933N1

Enrollment

Registered

2013-06-12

Start date

2013-05-07

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabet. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention group: Forty-two Patients in addition to previous medications, a new lifestyle, Herbal Capsule Berberine 500 mg twice per day, every twelve hours for four weeks. Interven

Placebo

Intervention group: Forty-two Patients in addition to previous medications, a new lifestyle, Herbal Capsule Berberine 500 mg twice per day, every twelve hours for four weeks.

Control group: Forty-two Patients in addition to previous medications, a new lifestyle, placebo Capsule 500 mg twice per day, every twelve hours for four weeks

Eligibility

Sex/Gender

All

Age

30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age 30-65 years; HbA1C 7-8.5; Fasting Blood Sugar 126 -200; diagnosis of Diabetes less than 10 years; Only use oral blood glucose lowering drugs . Exclusion critria: Fasting Blood Sugar More Than 200; HbA1C More Than 8.5 ;triglyceride More Than 500; pregnancy; Consumers of anticoagulants drugs (except Aspirin); chronic liver disease except fatty liver disease; proliferative Diabetic retinopathy; Renal Failure; Heart failure; Hemorrhagic strokes; hypothyroidism and hyperthyroidism; treatment with Insulin.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting Blood Sugar. Timepoint: baseline , after four weeks. Method of measurement: Blood samples from patients, mg/dl.;2hpp( 2 hour post prandial). Timepoint: baseline , after four weeks. Method of measurement: Blood samples from patients, mg/dl.;Fructosamine. Timepoint: baseline , after four weeks. Method of measurement: Blood samples from patients ,umol.	—

Secondary

Measure	Time frame
Lipid profile. Timepoint: baseline , after four weeks. Method of measurement: Blood samples from patients,Mg per deciliter.;Blood pressure. Timepoint: baseline , after four weeks. Method of measurement: Manometer, mmHg.;Body Mass Index. Timepoint: baseline , after four weeks. Method of measurement: Scale,Meter,Kg/m2.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Mehraban, MD

Ahvaz Jundishapur University of Medical Sciences

Mehraban.z@ajums.ac.ir &Dr.mehraban90@gmail.com+98 61 1336 1984

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026